Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.43 |
| ▸ | KLK1 | P06870 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6944295 | 0.84 | MEN1 (0.58) | MEN1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL7425506 | 0.84 | CYP3A4 (0.49) | MEN1KMT2AAKR1B1HPGDCYP1A2 | |
| SCHEMBL6946378 | 0.82 | MEN1 (0.52) | MEN1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL6942084 | 0.82 | MMP13 (0.57) | MEN1KMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL6943714 | 0.81 | HPGD (0.46) | MEN1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL6940041 | 0.81 | MEN1 (0.54) | MEN1KMT2AAKR1B1HPGDCYP1A2 | |
| SCHEMBL31171390 | 0.80 | KMT2A (0.51) | KMT2AAKR1B1CYP1A2CYP2C19EPHX2 | |
| SCHEMBL6942032 | 0.80 | FFAR1 (0.58) | MEN1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL6941766 | 0.79 | MEN1 (0.54) | MEN1KMT2AHPGDCYP1A2CYP3A4 | |
| SCHEMBL6941580 | 0.78 | HPGD (0.54) | MEN1KMT2AAKR1B1HPGDCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
| EP-1080069-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999054284-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | MEN1 2660/4885KMT2A 1991/4885AKR1B1 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.